SLC5A2 and heart failure: Nevertheless, results from meta-analyses of the earlier reported SGLT-2 inhibitor trials in type 2 DM encouragingly suggest renal benefits may extend to people without albuminuria [44], as do eGFR slope-based analyses in the trials among people with heart failure [20, 21, 45, 46].